<!-- fixture-id: 20 -->
<!-- expected-kind: none -->
<!-- captured: 2026-04-16T21:25:00Z -->
<!-- source: synthetic — hand-written for pressure testing -->
<!-- turns: 14 -->

## Turn 1 — User
Three things tangled together this session: research the current state of US data-residency requirements for healthcare data, plan our compliance project to meet them, and draft the announcement email to the engineering team. Hop between as you make progress.

## Turn 2 — Agent
I'll work the research in stages — first scope, then search, then verify — and slot the planning and email work in alongside.

Stage 1 — research scope: focusing on US federal and state data-residency rules that apply to PHI, since that's our actual data class. Step 1 is bounding the question to PHI under HIPAA and state-level supplements (CCPA, NY SHIELD, Texas HB 300).

## Turn 3 — User
Right. While you do step 2, draft the opening of the announcement email. Audience is the engineering org, tone should be matter-of-fact, no alarmism.

## Turn 4 — Agent
Email draft, opening:

> Subject line: Compliance project starting Q3 — data residency for PHI
>
> Hi all,
>
> We're kicking off a compliance project this quarter to bring our PHI handling in line with current US data-residency requirements. Format as: short context, then what's changing, then what we need from each team. Happy to revise tone if "matter-of-fact" reads as too dry.

Continuing the research stage in parallel.

## Turn 5 — Agent
Step 2 — search. HIPAA itself does not impose a strict US-only residency requirement for PHI; it requires safeguards regardless of location. The state-level rules vary: Texas HB 300 has stricter consent requirements than HIPAA but no residency rule; NY SHIELD requires reasonable safeguards but no residency rule; CCPA covers personal information broadly but exempts PHI handled under HIPAA.

Stage 3 — verify against the statute texts: confirmed HIPAA has no explicit US-residency requirement (45 CFR 164.308 covers safeguards, not location). The "data residency" framing turns out to be vendor-marketing convention more than statutory text.

## Turn 6 — User
That changes the planning. Walk through the project plan now — what stages, what goes in each.

## Turn 7 — Agent
Plan, broken into stages. The user must approve before I start any of them.

> **Stage 1 — inventory.** Catalog every system holding PHI and where its storage lives today. Step 1 is the inventory — without it we cannot make claims about residency one way or the other.
>
> **Stage 2 — gap analysis.** For each system, compare current storage location against the applicable rule (HIPAA safeguards everywhere; state-specific consent rules where the patient resides). Output: a table of systems × applicable obligations × gaps.
>
> **Stage 3 — remediation.** For each gap, decide: fix in place (encrypt, restrict access), migrate (move data to a compliant store), or document (no fix needed because the original concern was vendor-marketing framing, not law).
>
> **Stage 4 — attestation.** Sign-off from compliance counsel and security. Loop back to stage 2 if counsel disagrees with our gap classifications.

## Turn 8 — User
Approved. Drop the plan summary into the email — same matter-of-fact tone, formatted as four short paragraphs.

## Turn 9 — Agent
Revising the email body to incorporate the plan:

> Hi all,
>
> We're kicking off a compliance project this quarter to bring our PHI handling in line with current US requirements. Heads up: "data residency" is partly a vendor-marketing framing — HIPAA itself does not impose a strict US-only storage rule. What does apply is HIPAA's safeguards regardless of location, plus state-specific consent rules (Texas HB 300, NY SHIELD).
>
> The project has four stages: inventory of every PHI system, gap analysis against the actual obligations, remediation for the real gaps, and counsel sign-off. We expect most "gaps" to fall into the "no fix needed — document the reasoning" bucket; the work is mostly in the inventory and gap analysis.
>
> What we need from each team: a list of every service that touches PHI and where its primary storage lives, by Friday August 8. Template attached.
>
> Reach out with questions; happy to walk anyone through it.
>
> Thanks,
> Priya

## Turn 10 — User
Good. Revise the second paragraph — say "four stages" but name them so engineers know which one their team will hit first.

## Turn 11 — Agent
Revised paragraph:

> The project has four named stages: **(1) inventory** — every team catalogs PHI-touching services by August 8; **(2) gap analysis** — compliance team compares current state to actual obligations through August; **(3) remediation** — engineering work in September, scoped per gap; **(4) attestation** — counsel sign-off in early October. Stage 1 is the only stage that needs work from every engineering team; the rest is centralized.

## Turn 12 — User
Now go back to the research — what about future state laws? Anything pending that would change the residency picture?

## Turn 13 — Agent
Going back to the search step on pending state legislation.

Step 2 (revisited): scanning state-legislation trackers for 2026 sessions. Two bills worth flagging: Washington HB 1971 (proposes consent rules similar to Texas HB 300, no residency component) and Florida SB 262 (proposes a US-residency requirement for "sensitive health data" handled by entities above a revenue threshold, currently in committee).

Then step 3 (revisited): verified Florida SB 262 is in committee as of April 2026, not enacted. Worth mentioning in the email as "monitor" rather than as "comply with."

## Turn 14 — Agent
Adding a fourth paragraph to the email:

> One forward-looking item: Florida SB 262 (in committee as of April) would introduce a US-residency requirement for sensitive health data above a revenue threshold. We're monitoring it but not building toward it until it advances out of committee.

Final email below — research, plan, and draft all reflect the same set of facts.
